Encased tamper resistant controlled release dosage forms
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/20
A61K-009/24
A61K-031/485
A61K-009/00
출원번호
US-0045962
(2016-02-17)
등록번호
US-9572779
(2017-02-21)
발명자
/ 주소
Huang, Haiyong Hugh
출원인 / 주소
Purdue Pharma L.P.
대리인 / 주소
Lowenstein Sandler LLP
인용정보
피인용 횟수 :
2인용 특허 :
224
초록▼
In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispers
In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
대표청구항▼
1. A solid controlled release dosage form comprising: a core comprising a first portion of hydrocodone or a pharmaceutically acceptable salt thereof dispersed in a first matrix material; anda shell encasing the core and comprising a second portion of the hydrocodone or pharmaceutically acceptable sa
1. A solid controlled release dosage form comprising: a core comprising a first portion of hydrocodone or a pharmaceutically acceptable salt thereof dispersed in a first matrix material; anda shell encasing the core and comprising a second portion of the hydrocodone or pharmaceutically acceptable salt thereof dispersed in a second matrix material;wherein the amount of hydrocodone or pharmaceutically acceptable salt thereof released from the dosage form, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C., at 2 hours, is less than about 25%; at 4 hours, is from about 10% to about 30%; at 8 hours, is from about 20% to about 60%; at 12 hours, is from about 40% to about 90%; and at 18 hours, is greater than about 70%; andwherein the amount of hydrocodone or pharmaceutically acceptable salt thereof released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C. 2. The solid controlled release dosage form of claim 1, wherein the first matrix material, the second matrix material, or both the first and second matrix material comprises polyethylene oxide. 3. The solid controlled release dosage form of claim 2, wherein the polyethylene oxide has an average molecular weight from about 300,000 to about 10,000,000. 4. The solid controlled release dosage form of claim 2, wherein the polyethylene oxide has an average molecular weight from about 1,000,000 to about 10,000,000. 5. The solid controlled release dosage form of claim 2, wherein the first matrix material, the second matrix material, or both the first and second matrix material comprises a cellulose ether. 6. The solid controlled release dosage form of claim 5, wherein the first matrix material, the second matrix material, or both the first and second matrix material comprises a hydroxyalkylcellulose. 7. The solid controlled release dosage form of claim 6, wherein the hydroxyalkylcellulose is hydroxypropylcellulose. 8. The solid controlled release dosage form of claim 5, wherein the first matrix material, the second matrix material, or both the first and second matrix material comprises microcrystalline cellulose. 9. The solid controlled release dosage form of claim 8, comprising a compressed dispersion of the hydrocodone or pharmaceutically acceptable salt thereof and the matrix material. 10. The solid controlled release dosage form of claim 8, comprising granules comprising the hydrocodone or pharmaceutically acceptable salt thereof and the first matrix material. 11. The solid controlled release dosage form of claim 10, wherein the granules are compressed into a tablet. 12. The solid controlled release dosage form of claim 8, wherein the hydrocodone or pharmaceutically acceptable salt thereof is hydrocodone bitartrate. 13. The solid controlled release dosage form of claim 12, wherein the total amount of hydrocodone bitartrate in the dosage form is from about 0.5 mg to about 1250 mg. 14. The solid controlled release dosage form of claim 8, which provides a C24/Cmax ratio of hydrocodone of about 0.55 to about 1.0 after oral administration to a subject. 15. The solid controlled release dosage form of claim 8, which provides a Tmax (h) of hydrocodone from about 4 to about 20 hours after oral administration to a subject. 16. The solid controlled release dosage form of claim 14, wherein the administration is a first administration to a population of subjects. 17. The solid controlled release dosage form of claim 14, wherein the administration is steady state administration to a subject. 18. The solid controlled release dosage form of claim 8, which contains about 20 mg hydrocodone or pharmaceutically acceptable salt thereof. 19. The solid controlled release dosage form of claim 8, which contains about 120 mg hydrocodone or pharmaceutically acceptable salt thereof. 20. The solid controlled release dosage form of claim 8, which provides a mean AUC (ng*h/mL) after oral administration to a subject of about 250 to 400 per each 20 mg hydrocodone or pharmaceutically acceptable salt thereof included in the dosage form. 21. The solid controlled release dosage form of claim 8, which provides a mean Cmax (ng/mL) after oral administration to a subject of about 10 to about 30 per each 20 mg hydrocodone or pharmaceutically acceptable salt thereof included in the dosage form. 22. The solid controlled release dosage form of claim 8, which provides a mean Tmax (h) after oral administration to a subject of about 10 to about 20. 23. The solid controlled release dosage form of claim 8, which provides a mean T1/2 (h) after oral administration to a subject of about 5 to about 10. 24. The solid controlled release dosage form of claim 8, which provides a mean Tlag (h) after oral administration to a subject of about 0.01 to about 0.2. 25. The solid controlled release dosage form of claim 8, wherein the mean C24/Cmax ratio is about 0.2 to about 0.8 after oral administration to a subject. 26. The solid controlled release dosage form of claim 25, wherein the administration is in the fasted state. 27. The solid controlled release dosage form of claim 8, wherein the mean AUC (ng*h/mL) after oral administration to a subject in the fed state is less than 20% higher than the AUC (ng*h/mL) after oral administration to a subject in the fasted state. 28. The solid controlled release dosage form of claim 8, wherein the mean Cmax (ng/mL) after oral administration to a subject in the fed state is less than 80% higher than the Cmax after oral administration to a subject in the fasted state. 29. The solid controlled release dosage form of claim 8, wherein the mean Tmax (h) after oral administration to a subject in the fed state is within 25% of the Tmax (h) after oral administration to a subject in the fasted state. 30. The solid controlled release dosage form of claim 8, wherein the mean T1/2 (h) after oral administration to a subject in the fed state is within 8% of the T1/2 after oral administration to a subject in the fasted state.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (224)
Khanna Ish K. (Vernon Hills IL) Weier Richard M. (Lake Bluff IL) Collins Paul W. (Deerfield IL) Yu Yi (Skokie IL) Xu Xiangdong (Evanston IL) Partis Richard A. (Evanston IL) Koszyk Francis J. (Prospec, 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation.
Black Cameron (Pointe Claire CAX) Mancini Joseph A. (St. Leonard CAX) Lau Cheuk K. (Ile Bizard CAX) Prasit Petpiboon (Kirkland CAX) Vickers Philip J. (Pierrefonds CAX 4), 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents.
Hirsh,Jane; Kibanov,Alexander M.; Swager,Timothy M.; Buchwald,Stephen L.; Lo,Whe Yong; Fleming,Alison B.; Rariy,Roman V., Abuse-deterrent pharmaceutical compositions of opiods and other drugs.
Black W. Cameron (Pointe-Claire CAX) Li Chun-Sing (Dollard Des Ormeaux CAX) Guay Daniel (Notre Dame de L\lle Perrot CAX) Prasit Petpiboon (Kirkland CAX) Roy Patrick (Dollard Des Ormeaux CAX), Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) McGinity James (Austin TX) Bodmeier Roland (Austin TX), Aqueous dispersions of zein and preparation thereof.
Gauthier Jacques Y. (Laval CAX) Lau Cheuk K. (Ile Bizard CAX) LeBlanc Yves (Kirkland CAX) Li Chun-Sing (Dollard des Ormeaux CAX) Roy Patrick (Dollard des Ormeaux CAX) Therien Michel (Laval CAX) Wang , Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents.
Leshchiner Edward (Cresskill NJ) Balazs Endre A. (Fort Lee NJ) Larsen Nancy E. (Highland Mills NY) Leshchiner Adelva (Cresskill NJ), Biocompatible viscoelastic gel slurries, their preparation and use.
Kuczynski Anthony L. ; Childers Jerry D. ; Barclay Glen E. ; Rodriguez Susan ; Merrill Sonya, Composition and dosage form comprising opioid antagonist.
Blumberg Peter M. (Frederick MD), Composition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitizat.
Drust Eugene G. (Norwich NY) Kasting Gerald B. (Wyoming OH) Smith Ronald L. (West Chester OH) Szkutak Joan B. (West Chester OH), Compositions for the transdermal delivery of pharmaceutical actives.
Oshlack Benjamin (New York NY) McGinity James (Austin TX) Chasin Mark (Manalapan NJ) Bodmeier Roland (Austin TX), Controlled release coatings derived from aqueous dispersions of zein.
Goldie Robert S. (Cambridge GB2) Malkowska Sandra T. A. (Cambridge GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release dihydrocodeine composition.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Goldie Robert S. (Comberton GB2) Malkowska Sandra T. A. (Landbeach GB2) Leslie Stewart T. (Cambridge GB2) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
Goldie Robert S. (Comberton GBX) Malkowska Sandra T. A. (Landbeach GBX) Leslie Stewart T. (Cambridge GBX) Miller Ronald B. (Basel CHX), Controlled release hydromorphone composition.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John Joseph (Mount Vernon NY) Kaiko Robert Francis (Weston CT), Controlled release oxycodone compositions.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled-release formulations coated with aqueous dispersions of ethylcellulose.
Prasit Petpiboon (Kirkland CAX) Guay Daniel (Iie Perrot CAX) Wang Zhaoyin (Pierrefonds CAX) Leger Serge (Dollar des Ormeaux CAX) Therien Michel (Laval CAX), Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2.
Bjork, Anders K. K.; Olsson, Knut G.; Abramo, Aina L.; Christensson, Erik G., Diphenylbutyl-piperazinecarboxamides in pharmaceutical compositions and methods.
Sawada, Toyohiro; Sako, Kazuhiro; Yoshioka, Tatsunobu; Watanabe, Shunsuke, Drug delivery system for averting pharmacokinetic drug interaction and method thereof.
Han, Chien-Hsuan; Hou, Sui Yuen Eddie; Reid, Monica L., Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic.
Mayer, David J.; Price, Donald D.; Mao, Jianren; Lyle, John W., Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance.
Mayer David J. (Richmond VA) Price Donald D. (Richmond VA) Mao Jianren (Richmond VA) Lyle John W. (Belmar NJ), Inhibiting the development of tolerance to and/or dependence on an addictive substance.
Crain Stanley M. (Leonia NJ) Shen Ke-fei (Flushing NY), Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other o.
Sackler Richard S. (Greenwich CT) Kaiko Robert F. (Weston CT) Goldenheim Paul (Wilton CT), Method of treating pain by administering 24 hour oral opioid formulations.
Sackler Richard (Greenwich CT) Goldenheim Paul (Wilton CT) Kaiko Robert (Weston CT), Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasm.
Kumar, Vijai; Dixon, David; Tewari, Divya; Wadgaonkar, Dilip B., Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof.
Colombo Paolo (Milan ITX) Cardona Antonio C. (Milan ITX) Pifferi Giorgio (Milan ITX), Multilayer matrix systems for the controlled release of active principles.
Lau Cheuk Kun (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques-Yves (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducha, N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Belley Michel (Pierrefonds CAX), N-benzyl-3-indoleacetic acids as antiinflammatory drugs.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques Y. (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducharme, N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors.
Houn Simon Hsia ; David Fan, Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates.
Shaw Irving F. (East Rockaway NY) Berk Jerome (New Rochelle NY), Orally administered drug composition for therapy in the treatment of narcotic drug addiction.
Wong Patrick S. L. (Hayward CA) Barclay Brian L. (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device for administering certain drugs.
Wong Patrick S. L. (Hayward CA) Barclay Brian (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device with dual thermodynamic activity.
Guillaumet Grald (Orleans FRX) Flouzat Christine (Clermont Ferrand FRX) Devissaguet Michelle (Neuilly sur Seine FRX) Renard Pierre (Versailles FRX) Caignard Daniel H. (Paris FRX) Adam Grard (le Mesni, Oxazolopyridine compounds, compositions and use.
Fukunaga Atsuo F. (5411 Littlebow Rd. Rancho Palos Verdes CA 90274) Funuknaga Alex S. (5411 Littlebow Rd. Rancho Palos Verdes CA 90274), Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine.
Batt Douglas G. (Wilmington DE) Pinto Donald J. P. (Newark DE) Orwat Michael J. (Wilmington DE) Petraitis Joseph J. (Glenmoore PA) Pitts William J. (Newark DE), Prostaglandin synthase inhibitors.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release formulations having acrylic polymer coating.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Jackson Heights NY) Gaylord Norman G. (New Providence NJ), Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose.
Staniforth John N.,GB2 ; Sherwood Bob E. ; Hunter Edward A., Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility.
Chien Yie W. (North Brunswick NJ) Chiang Chin-Chih (Piscataway NJ) Tojo Kabuji (Highland Park NJ), Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration.
Gale Robert M. (Los Altos CA) Goetz Victor (Palo Alto CA) Lee Eun S. (Redwood City CA) Taskovich Lina T. (Palo Alto CA) Yum Su I. (Los Altos CA), Transdermal administration of fentanyl and device therefor.
Hille Thomas (Neuwied DEX) Deurer Lothar (Koblenz DEX) Hoffmann Hans-Rainer (Neuwied DEX), Transdermal therapeutic system comprising as active component buprenorphine.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.